Drug intelligence / Profile preview

HiCM-388

Development stage: Preclinical
Lead developer: Help Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intramyocardial, Intracoronary

Overview

HiCM-388 is an allogeneic, off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs), developed by Help Therapeutics for the treatment of cardiovascular diseases, including ST-elevation myocardial infarction (STEMI). The therapy utilizes iPSC-derived cells, specifically cardiomyocytes, intended for tissue regeneration and replacement in damaged cardiac tissue. As a regenerative cell therapy, it does not target a specific molecular pathway but rather aims to restore heart function by replacing lost or damaged cells. Help Therapeutics has received IND approval for HiCM-388, positioning it as a clinical-stage asset within their pipeline of iPSC-based regenerative medicines.

Beyond the preview

Go deeper on HiCM-388.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HiCM-388.

Explore the full profile